Physician profile
Eric Vance
NPI 1265033435
$7,500.99
in general payments reported to CMS, 2019-2025
36 companies · $877 in 2025
The $877 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,130 · 2022: $1,193 · 2023: $2,008 · 2024: $2,293 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,079 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,079.41 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,358.77 | 2021-2025 | |
| Glaxosmithkline, LLC. | $935.39 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $681.32 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $577.64 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $564.73 | 2023-2025 | |
| Lilly USA, LLC | $520.39 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $474.01 | 2023-2025 | Nuedexta, Rexulti |
| Ironshore Pharmaceuticals INC. | $301.09 | 2021-2023 | Jornay Pm |
| Si-Bone, INC. | $168.67 | 2024 | |
| Lundbeck LLC | $167.57 | 2023-2025 | Vyepti, Rexulti |
| Acerus Pharmaceuticals Corporation | $166.89 | 2021-2022 | |
| Exact Sciences Corporation | $149.08 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $147.14 | 2021-2024 | Trintellix |
| Astellas Pharma US INC | $134.47 | 2024-2025 | Veozah |
| Abbott Laboratories | $134.18 | 2021-2024 | Freestyle Libre 3, Proclaim |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $118.65 | 2024 | Auvelity |
| Impulse Dynamics (USA) INC. | $115.02 | 2023 | Optimizer |
| Pfizer INC. | $105.29 | 2023-2025 | |
| Shield Therapeutics INC | $98.28 | 2022-2025 | |
| Medtronic, INC. | $67.91 | 2022 | |
| Scilex Pharmaceuticals INC. | $53.49 | 2023-2024 | Ztlido |
| Alk-Abello, INC | $51.80 | 2023-2024 | Ragwitek, Grastek, Odactra |
| Clarus Therapeutics INC. | $45.67 | 2021 | |
| Genentech USA, INC. | $42.02 | 2021 | |
| Supernus Pharmaceuticals, INC. | $40.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.19 | 2023-2025 | Caplyta |
| Antares Pharma, INC. | $35.07 | 2021-2022 | |
| Tolmar, INC. | $31.42 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.02 | 2025 | Xifaxan |
| Amgen INC. | $28.86 | 2024 | Repatha, Otezla |
| Exeltis, USA INC. | $24.06 | 2024 | Slynd |
| Philips North America LLC | $22.76 | 2024 | (Ck7) Extended Holter |
| Dexcom, INC. | $21.92 | 2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $17.93 | 2021 | |
| Neos Therapeutics, Lp | $15.75 | 2021 | |
| Corium, LLC | $15.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.